The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

We recently compiled a list of the 10 Best UK Stocks to Invest in ... and Imfinzi as key differentiators. AstraZeneca PLC ...

Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge ...

AstraZeneca Plc said its experimental obesity ... in nausea and vomiting,” as can be expected with this type of drug, said Sharon Barr, executive vice-president of biopharmaceuticals R&D.

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

AstraZeneca (AZN) stock falls as a Chinese probe into drug importations and data privacy implicates senior and former ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be implicated in the largest insurance fraud case ...